|
Biologics are the fastest-growing area in the biopharmaceutical space, forecasted to be six of the top ten drugs by 2014. Current delivery methods for these drugs require large-volume administration of an aqueous injection or infusion, usually in a clinical setting. As expected, this results in a poor patient experience making many diseases difficult to manage. Complicated and unpleasant administration also reduces compliance and leads to higher costs of administration.
We aspire to change the paradigm for injection by developing ultra-low-volume, ready-to-use pharmaceuticals delivered through patient-friendly injection devices. Many of these devices would be self-administered in the comfort of the patient’s home. We also pursue business development opportunities in applying our novel technologies to support partner development efforts for their own proprietary programs and products. Products developed leveraging Xeris’ non-aqueous formulation and delivery technologies will establish a new model, eliminating reconstitution, simplifying administration, and easing the pain of injections for millions of patients and caregivers.
|
